Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($30.07); post-transaction worth based connected March 10, 2026, marketplace adjacent ($30.24).

• What was the operation and information down this transaction?
  This was an exercise-and-sell lawsuit successful which Collins converted 40,000 banal options to Common Stock and instantly sold the resulting shares, accordant with liquidity absorption and not an open-market discretionary sale.

• How did this merchantability impact Collins’s nonstop Common Stock ownership?
  The transaction near her nonstop communal banal holdings unchanged astatine 25,000 shares.

• What continuing equity vulnerability does Collins support pursuing this transaction?
  Collins holds 25,000 communal shares and 181,268 banal options.

Note: 1-year show calculated utilizing March 27th, 2026, arsenic the notation date.

• Pipeline includes tiny molecule kinase inhibitors specified arsenic ELVN-001 (targeting chronic myeloid leukemia) and ELVN-002 (targeting HER2-mutant cancers), some successful Phase 1 objective trials.

• Operates a clinical-stage biopharmaceutical concern exemplary focused connected processing proprietary oncology therapies for aboriginal commercialization oregon licensing.

• Primary customers are anticipated to beryllium healthcare providers, hospitals, and oncology specialists treating patients with cancer.

Enliven Therapeutics is simply a clinical-stage biotechnology institution based successful Boulder, Colorado, with a absorption connected processing innovative small-molecule therapies for cancer. The institution leverages a targeted attack to cause discovery, aiming to code unmet needs successful oncology done its kinase inhibitor pipeline. With a thin workforce and a robust early-stage portfolio, Enliven Therapeutics positions itself to vie successful the evolving scenery of precision crab therapeutics.

Eliven Therapeutics’ Chief Medical Officer whitethorn beryllium kicking herself for not waiting a fewer weeks. The banal finished March 27 astatine $38.83 per share, or   astir 28.5% supra the mean merchantability terms she reported earlier this month.